Drugmakers Regeneron Pharmaceuticals, Inc., and Sanofi SA recently announced plans to cut the price of Praluent.
Praluent, a cholesterol-lowering drug, could reach a price range between $4,500-$8,000 after the drugmakers renegotiate their contracts with insurers, according to a MarketWatch report.
The net price range is based off the Institute for Clinical and Economic Review’s cost-effectiveness analysis.
“Enough is enough,” Regeneron CEO Leonard Schleifer said in an interview. “We’re willing to work in their range, providing that payers agree to reduce their burdensome barriers for patients.
